Systemic sclerosis - Dermatological aspects. Part 1: Pathogenesis, epidemiology, clinical findings;Systemische Sklerodermie - Fokus dermatologischer Aspekte. Teil 1: Pathogenese, Epidemiologie, klinisches Bild

JDDG - Journal of the German Society of Dermatology

Volumn 10, Issue 10, 2012, Pages 705-716

  Sticherling, Michael ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

clinical findings; digital ulcers; organ involvement; pathogenesis; Raynaud phenomenon; systemic scleroderma

Indexed keywords

CENTROMERE ANTIBODY; DNA TOPOISOMERASE INHIBITOR; SCL 70 ANTIBODY;

ACRAL SCLERODERMA; ARTICLE; CLINICAL FEATURE; DIFFUSE SCLERODERMA; HUMAN; PATHOGENESIS; PREVALENCE; PULMONARY HYPERTENSION; SYSTEMIC SCLEROSIS;

EID: 84867101163     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2012.07999.x     Document Type: Article

References (44)

1. Denton CP, Black CM, Abraham DJ,. Mechanisms and consequences of fibrosis in systemic sclerosis. Nature Clin Prac Rheumatol 2006; 2: 134-44. (Pubitemid 43771821)
2. Toya SP, Tzelepis GE,. The many faces of scleroderma sine scleroderma: a literature review focusing on cardiopulmonary complications. Rheumatol Int 2009; 29: 861-8.
3. Katsumoto TR, Whitfield ML, Connolly MK,. The pathogenesis of systemic sclerosis. Annu Rev Pathol 2011; 6: 509-37.
4. Mahoney WM Jr, Fleming JN, Schwartz SM,. A unifying hypothesis for scleroderma: identifying a target cell for scleroderma. Curr Rheumatol Rep 2011; 13: 28-36.
5. Klein-Weigel P, Opitz C, Riemekasten G,. Systemic sclerosis-a systematic overview: part 1-disease characteristics and classification, pathophysiologic concepts, and recommendations for diagnosis and surveillance. Vasa 2011; 40: 6-19.
6. Artlett CM,. Animal models of scleroderma: fresh insights. Curr Opin Rheumatol 2010; 22: 677-82.
7. Lambert NC,. Microchimeric cells. Guardians or actors of immunity in scleroderma Rheumatology (Oxford) 2007, 46: 382-3. (Pubitemid 46344645)
8. Fleming JN, Shulman HM, Nash RA, Johnson PY, Wight TN, Gown A, Schwartz SM,. Cutaneous chronic graft-versus-host disease does not have the abnormal endothelial phenotype or vascular rarefaction characteristic of systemic sclerosis. PLoS One 2009; 4: e6203.
9. Martin J, Fonseca C,. The genetics of scleroderma. Curr Rheumatol Rep 2011; 13: 13-20.
10. Melchers I,. [Genetic analysis in collagen vascular diseases.]. Z Rheumatol 2011; 70: 192-7.
11. Radić M, Martinović Kaliterna D, Radić J,. Infectious disease as aetiological factor in the pathogenesis of systemic sclerosis. Neth J Med 2010; 68: 348-53.
12. Haustein UF, Herrmann K,. Environmental Scleroderma. Clin Dermatol 1994; 12: 467-73. (Pubitemid 24266932)
13. Wollheim FA,. Are occupational risk factors associated with markers of disease severity in patients with systemic scleroderma Nat Clin Pract Rheumatol 2006, 2: 12-3. (Pubitemid 43153641)
14. Mok MY, Yiu KH, Wong CY, Qiuwaxi J, Lai WH, Wong WS, Tse HF, Lau CS,. Low circulating level of CD133+KDR+cells in patients with systemic sclerosis. Clin Exp Rheumatol 2010; 28 (5 Suppl 62): S19-25.
15. Wei J, Bhattacharyya S, Tourtellotte WG, Varga J,. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev 2011; 10: 267-75.
16. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A,. Stimulatory autoanti-bodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354: 2667-76.
17. Baraut J, Michel L, Verrecchia F, Farge D,. Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis. Autoimmun Rev 2010; 10: 65-73.
18. Sakkas LI, Chikanza IC, Platsoukas CD,. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis. Nature Clin Prac Rheumatol 2006; 2: 679-85. (Pubitemid 44830857)
19. Harris ML, Rosen A,. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 2003; 15: 778-84. (Pubitemid 38156307)
20. Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
21. Hudson M, Taillefer S, Steele R, Dunne J, Johnson SR, Jones N, Mathieu JP, Baron M,. Improving the sensitivity of the American College of Rheumatology classification criteria for systemic sclerosis. Clin Exp Rheumatol 2007; 25: 754-7. (Pubitemid 350284851)
22. Nadashkevich O, Davis P, Fritzler MJ,. A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit 2004; 10: CR615-CR621. (Pubitemid 39546036)
23. Arbeitsgruppe Sklerodermie der Arbeitsgemeinschaft Dermatologische Forschung (ADF). Klinik der progressiven systemischen Sklerodermie (PSS). Hautarzt 1986; 37: 320-4.
24. Genth E, Krieg T,. Systemische Sklerose-Diagnose und Klassifikation. Z Rheumatol 2006; 65: 268-74. (Pubitemid 44124535)
25. Mayes MD,. Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29: 239-54. (Pubitemid 36765119)
26. Nguyen B, Mayes MD, Arnett FC, del Junco D, Reveille JD, Gonzalez EB, Draeger HT, Perry M, Hendiani A, Anand KK, Assassi S,. HLA-DRB1 0407 and 1304 are risk factors for scleroderma renal crisis. Arthritis Rheum 2011; 63: 530-4.
27. Hanke K, Becker MO, Brueckner CS, Meyer W, Janssen A, Schlumberger W, Hiepe F, Burmester GR, Riemekasten G,. Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis. J Rheumatol 2010; 37: 2548-52.
28. Nihtyanova SI, Parker JC, Black CM, Bunn CC, Denton C P,. A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis. Rheumatology (Oxford) 2009; 48: 1218-21.
29. Meyer O,. Prognostic markers for systemic sclerosis. Joint Bone Spine 2006; 73: 490-4.
30. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Muller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M,. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754-63. (Pubitemid 46846694)
31. Clements PJ, Roth MD, Elashoff R, Tashkin DP, Goldin J, Silver RM, Sterz M, Seibold JR, Schraufnagel D, Simms RW, Bolster M, Wise RA, Steen V, Mayes MD, Connelly K, Metersky M, Furst DE,. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis 2007; 66: 1641-7. (Pubitemid 350205454)
32. Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada-Y-Martin RM, Draeger H, Nair DK, Fritzler MJ, Reveille JD, Arnett FC, Mayes MD,; GENISOS Study Group. Predictors of interstitial lung disease in early systemic sclerosis: prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010; 12: R166.
33. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, Kuwana M, Yasuoka H, van den Hoogen F, Te Boome L, van Laar JM, Verbeet NL, Matucci-Cerinic M, Georgountzos A, Moutsopoulos HM,. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118: 2-10. (Pubitemid 40082450)
34. Sunderkötter C, Herrgott I, Brückner C, Moinzadeh P, Pfeiffer C, Gerss J, Hunzelmann N, Böhm M, Krieg T, Müller-Ladner U, Genth E, Schulze-Lohoff E, Meurer M, Melchers I, Riemekasten G,; DNSS Centers. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009; 160: 835-43.
35. Nihtyanova SI, Brough GM, Black CM, Denton CP,. Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2008; 67: 120-3.
36. Alivernini S, De Santis M, Tolusso B, Mannocci A, Bosello SL, Peluso G, Pinnelli M, D'Antona G, LaTorre G, Ferraccioli G,. Skin ulcers in systemic sclerosis: determinants of presence and predictive factors of healing. J Am Acad Dermatol 2009; 60: 426-35.
37. Clements PJ, Becvar R, Drosos AA, Ghattas L, Gabrielli A,. Assessment of gastrointestinal involvement. Clin Exp Rheumatol 2003; 21: S15-18.
38. Clements PJ, Furst DE,. Heart involvement in systemic sclerosis. Clin Dermatol 1994; 12: 267-75. (Pubitemid 24198733)
39. McNearney TA, Reveille JD, Fischbach M, Friedman AW, Lisse JR, Goel N, Tan FK, Zhou X, Ahn C, Feghali-Bostwick CA, Fritzler M, Arnett FC, Mayes MD,. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007; 57: 318-26. (Pubitemid 47164096)
40. Hunzelmann N, Riemekasten G,. [Pulmonary arterial hypertension in collagen disease: experiences of the German Network for Systemic Scleroderma]. Dtsch Med Wochenschr. 2006; 131: S325-7. (Pubitemid 46118441)
41. Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber H W, Whitfield ML, Lafyatis R,. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 2010; 5: e12106.
42. Trang G, Steele R, Baron M, Hudson M,. Corticosteroids and the risk of scleroderma renal crisis: a systematic review. Rheumatol Int 2012; 32: 645-53.
43. Mozzetta A, Antinone V, Alfani S, Neri P, Foglio Bonda PG, Pasquini P, Puddu P, Picardi A,. Mental health in patients with systemic sclerosis: a controlled investigation. J Eur Acad Dermatol Venereol 2008; 22: 336-40. (Pubitemid 351247424)
44. Baubet T, Ranque B, Taïeb O, Bérezné A, Bricou O, Mehallel S, Moroni C, Belin C, Pagnoux C, Moro MR, Guillevin L, Mouthon L,. Mood and anxiety disorders in systemic sclerosis patients. Presse Med 2011; 40: e111-9.